These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 9474242

  • 1. Antineoplastic agents 360. Synthesis and cancer cell growth inhibitory studies of dolastatin 15 structural modifications.
    Pettit GR, Flahive EJ, Boyd MR, Bai R, Hamel E, Pettit RK, Schmidt JM.
    Anticancer Drug Des; 1998 Jan; 13(1):47-66. PubMed ID: 9474242
    [Abstract] [Full Text] [Related]

  • 2. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
    Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Durkin KP, Boyd MR, Bai R, Hamel E, Schmidt JM, Chapuis JC.
    Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
    [Abstract] [Full Text] [Related]

  • 3. Antineoplastic agents 365. Dolastatin 10 SAR probes.
    Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Boyd MR, Hamel E, Pettit RK, Hogan F, Bai R, Chapuis JC, McAllister SC, Schmidt JM.
    Anticancer Drug Des; 1998 Jun; 13(4):243-77. PubMed ID: 9627667
    [Abstract] [Full Text] [Related]

  • 4. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
    Bai R, Roach MC, Jayaram SK, Barkoczy J, Pettit GR, Ludueña RF, Hamel E.
    Biochem Pharmacol; 1993 Apr 06; 45(7):1503-15. PubMed ID: 8471072
    [Abstract] [Full Text] [Related]

  • 5. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
    Bai R, Friedman SJ, Pettit GR, Hamel E.
    Biochem Pharmacol; 1992 Jun 23; 43(12):2637-45. PubMed ID: 1632820
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
    Poncet J, Busquet M, Roux F, Pierré A, Atassi G, Jouin P.
    J Med Chem; 1998 Apr 23; 41(9):1524-30. PubMed ID: 9554885
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interaction of marine toxin dolastatin 10 with porcine brain tubulin: competitive inhibition of rhizoxin and phomopsin A binding.
    Li Y, Kobayashi H, Hashimoto Y, Shirai R, Hirata A, Hayashi K, Hamada Y, Shioiri T, Iwasaki S.
    Chem Biol Interact; 1994 Dec 23; 93(3):175-83. PubMed ID: 7923438
    [Abstract] [Full Text] [Related]

  • 11. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
    Aherne GW, Hardcastle A, Valenti M, Bryant A, Rogers P, Pettit GR, Srirangam JK, Kelland LR.
    Cancer Chemother Pharmacol; 1996 Dec 23; 38(3):225-32. PubMed ID: 8646796
    [Abstract] [Full Text] [Related]

  • 12. Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.
    Cruz-Monserrate Z, Vervoort HC, Bai R, Newman DJ, Howell SB, Los G, Mullaney JT, Williams MD, Pettit GR, Fenical W, Hamel E.
    Mol Pharmacol; 2003 Jun 23; 63(6):1273-80. PubMed ID: 12761336
    [Abstract] [Full Text] [Related]

  • 13. Synthesis of Dolastatin 15 mimetic peptoids.
    Schmitt J, Bernd M, Kutscher B, Kessler H.
    Bioorg Med Chem Lett; 1998 Feb 17; 8(4):385-8. PubMed ID: 9871690
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and cytostatic properties of structure-simplified analogs of dolastatin 15.
    Hu MK, Huang WS.
    J Pept Res; 1999 Dec 17; 54(6):460-7. PubMed ID: 10604591
    [Abstract] [Full Text] [Related]

  • 15. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-Katib A.
    Clin Cancer Res; 1998 May 17; 4(5):1337-43. PubMed ID: 9607595
    [Abstract] [Full Text] [Related]

  • 16. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
    Bai R, Taylor GF, Cichacz ZA, Herald CL, Kepler JA, Pettit GR, Hamel E.
    Biochemistry; 1995 Aug 01; 34(30):9714-21. PubMed ID: 7626642
    [Abstract] [Full Text] [Related]

  • 17. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc.
    Turner T, Jackson WH, Pettit GR, Wells A, Kraft AS.
    Prostate; 1998 Feb 15; 34(3):175-81. PubMed ID: 9492845
    [Abstract] [Full Text] [Related]

  • 18. The dolastatins, a family of promising antineoplastic agents.
    Poncet J.
    Curr Pharm Des; 1999 Mar 15; 5(3):139-62. PubMed ID: 10066887
    [Abstract] [Full Text] [Related]

  • 19. The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog.
    Mooberry SL, Leal RM, Tinley TL, Luesch H, Moore RE, Corbett TH.
    Int J Cancer; 2003 Apr 20; 104(4):512-21. PubMed ID: 12584751
    [Abstract] [Full Text] [Related]

  • 20. Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin.
    Bai R, Verdier-Pinard P, Gangwar S, Stessman CC, McClure KJ, Sausville EA, Pettit GR, Bates RB, Hamel E.
    Mol Pharmacol; 2001 Mar 20; 59(3):462-9. PubMed ID: 11179440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.